[{"id":"88d90e77-172d-4510-b158-f4795d53f576","acronym":"CRESCENDO","url":"https://clinicaltrials.gov/study/NCT06072131","created_at":"2023-10-10T15:12:06.102Z","updated_at":"2024-07-02T16:35:00.782Z","phase":"Phase 3","brief_title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","source_id_and_acronym":"NCT06072131 - CRESCENDO","lead_sponsor":"Acrotech Biopharma Inc.","biomarkers":" ALK • TNFRSF8 • UGT1A1","pipe":" | ","alterations":" TNFRSF8 expression • UGT1A1*1*1","tags":["ALK • TNFRSF8 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)"],"overall_status":"Recruiting","enrollment":" Enrollment 504","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 11/01/2030","study_completion_date":" 11/01/2030","last_update_posted":"2024-05-27"},{"id":"52396473-78ff-4d4d-a535-0eca9ead2687","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598998","created_at":"2021-01-18T17:41:43.962Z","updated_at":"2024-07-02T16:35:16.011Z","phase":"Phase 1/2","brief_title":"Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas","source_id_and_acronym":"NCT03598998","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Folotyn (pralatrexate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 06/29/2024","study_completion_date":" 06/29/2024","last_update_posted":"2024-03-06"},{"id":"b84fa649-6a21-4a69-88fb-39a7bfebf3aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02422641","created_at":"2021-01-18T11:35:12.764Z","updated_at":"2024-07-02T16:35:19.750Z","phase":"Phase 2","brief_title":"Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis","source_id_and_acronym":"NCT02422641","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-12"},{"id":"c4a4883e-de84-42f0-8b66-0e5ccb6e66a9","acronym":"NRG-LU008","url":"https://clinicaltrials.gov/study/NCT05624996","created_at":"2022-11-22T15:59:02.499Z","updated_at":"2024-07-02T16:35:20.409Z","phase":"Phase 3","brief_title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05624996 - NRG-LU008","lead_sponsor":"NRG Oncology","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 474","initiation":"Initiation: 05/10/2023","start_date":" 05/10/2023","primary_txt":" Primary completion: 10/15/2031","primary_completion_date":" 10/15/2031","study_txt":" Completion: 10/15/2036","study_completion_date":" 10/15/2036","last_update_posted":"2024-02-07"},{"id":"23e0ae17-59f0-4190-ae9d-2a3bb406aa11","acronym":"G360-IIT","url":"https://clinicaltrials.gov/study/NCT05715229","created_at":"2023-02-06T15:03:00.616Z","updated_at":"2024-07-02T16:35:23.375Z","phase":"Phase 2","brief_title":"Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy","source_id_and_acronym":"NCT05715229 - G360-IIT","lead_sponsor":"Hackensack Meridian Health","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/29/2023","start_date":" 09/29/2023","primary_txt":" Primary completion: 04/28/2026","primary_completion_date":" 04/28/2026","study_txt":" Completion: 04/28/2026","study_completion_date":" 04/28/2026","last_update_posted":"2024-01-15"},{"id":"ae4f0bcf-92e9-4aec-bed9-90d3c7787dc5","acronym":"BRE-08","url":"https://clinicaltrials.gov/study/NCT06085742","created_at":"2023-10-17T15:12:33.591Z","updated_at":"2024-07-02T16:35:23.572Z","phase":"Phase 2","brief_title":"BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer","source_id_and_acronym":"NCT06085742 - BRE-08","lead_sponsor":"University of Illinois at Chicago","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • methotrexate"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/22/2023","start_date":" 11/22/2023","primary_txt":" Primary completion: 09/01/2034","primary_completion_date":" 09/01/2034","study_txt":" Completion: 09/01/2034","study_completion_date":" 09/01/2034","last_update_posted":"2024-01-12"},{"id":"ef86a3a8-542d-441c-8140-8447052c1fb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05764928","created_at":"2023-03-13T15:02:10.577Z","updated_at":"2024-07-02T16:35:28.639Z","phase":"Phase 1/2","brief_title":"Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy","source_id_and_acronym":"NCT05764928","lead_sponsor":"Rgene Corporation","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-11-20"},{"id":"7b581477-ebf0-4026-ad4e-d6537f45d18d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02426658","created_at":"2021-01-18T11:36:29.773Z","updated_at":"2024-07-02T16:35:33.802Z","phase":"Phase 2","brief_title":"Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3","source_id_and_acronym":"NCT02426658","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ROS1 mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/19/2018","primary_completion_date":" 04/19/2018","study_txt":" Completion: 10/07/2022","study_completion_date":" 10/07/2022","last_update_posted":"2023-10-12"},{"id":"6534377c-261b-484f-9214-3050310c7c27","acronym":"","url":"https://clinicaltrials.gov/study/NCT01336933","created_at":"2021-01-18T05:27:06.399Z","updated_at":"2024-07-02T16:35:36.065Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01336933","lead_sponsor":"University of Nebraska","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • vincristine • prednisone • Folotyn (pralatrexate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 07/06/2011","start_date":" 07/06/2011","primary_txt":" Primary completion: 12/28/2016","primary_completion_date":" 12/28/2016","study_txt":" Completion: 12/28/2016","study_completion_date":" 12/28/2016","last_update_posted":"2023-09-22"},{"id":"6ac89698-feea-45c6-890c-6fbc31394027","acronym":"IFCT-1201","url":"https://clinicaltrials.gov/study/NCT01850303","created_at":"2021-01-18T08:15:32.988Z","updated_at":"2024-07-02T16:35:53.399Z","phase":"Phase 3","brief_title":"Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01850303 - IFCT-1201","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 632","initiation":"Initiation: 05/16/2013","start_date":" 05/16/2013","primary_txt":" Primary completion: 08/20/2018","primary_completion_date":" 08/20/2018","study_txt":" Completion: 01/31/2020","study_completion_date":" 01/31/2020","last_update_posted":"2023-03-14"},{"id":"9dcd3182-a043-4694-8023-115c44b472ad","acronym":"CHIVA","url":"https://clinicaltrials.gov/study/NCT01296113","created_at":"2021-01-29T07:01:38.615Z","updated_at":"2024-07-02T16:35:53.388Z","phase":"Phase 2","brief_title":"Chemotherapy for Lung Cancer in HIV-positive Patients","source_id_and_acronym":"NCT01296113 - CHIVA","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 07/01/2017","study_completion_date":" 07/01/2017","last_update_posted":"2023-03-14"},{"id":"01d7872c-62e6-480f-8138-2caec3d153a4","acronym":"METHOGLU","url":"https://clinicaltrials.gov/study/NCT05135858","created_at":"2021-11-26T14:53:40.439Z","updated_at":"2024-07-02T16:36:01.882Z","phase":"Phase 1","brief_title":"Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma","source_id_and_acronym":"NCT05135858 - METHOGLU","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" IL10","pipe":"","alterations":" ","tags":["IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2022-10-25"},{"id":"35e30234-162e-4d4d-9d1e-a643e2c4f332","acronym":"","url":"https://clinicaltrials.gov/study/NCT05522582","created_at":"2022-08-31T16:59:08.947Z","updated_at":"2024-07-02T16:36:02.903Z","phase":"Phase 2","brief_title":"Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors","source_id_and_acronym":"NCT05522582","lead_sponsor":"Yancheng First People's Hospital","biomarkers":" CD8 • IL6 • CD4","pipe":"","alterations":" ","tags":["CD8 • IL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/15/2021","start_date":" 11/15/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-10-06"},{"id":"e0760145-1870-4eb2-bfda-4eec6ab03abe","acronym":"NCI-2018-02609","url":"https://clinicaltrials.gov/study/NCT03518242","created_at":"2021-01-18T17:19:06.525Z","updated_at":"2025-02-25T13:18:30.911Z","phase":"Phase 1","brief_title":"Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer","source_id_and_acronym":"NCT03518242 - NCI-2018-02609","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • methotrexate • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 06/06/2018","start_date":" 06/06/2018","primary_txt":" Primary completion: 05/04/2022","primary_completion_date":" 05/04/2022","study_txt":" Completion: 05/04/2022","study_completion_date":" 05/04/2022","last_update_posted":"2022-06-08"},{"id":"5be61f83-2017-482b-b975-53687f1a8509","acronym":"","url":"https://clinicaltrials.gov/study/NCT02303899","created_at":"2021-01-18T10:53:45.455Z","updated_at":"2024-07-02T16:36:35.735Z","phase":"Phase 2","brief_title":"Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma","source_id_and_acronym":"NCT02303899","lead_sponsor":"Istituto Clinico Humanitas","biomarkers":" KIT • PDGFRB","pipe":"","alterations":" ","tags":["KIT • PDGFRB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • imatinib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2021-01-22"},{"id":"63d27786-955f-456f-9b97-5a7e4032fa84","acronym":"","url":"https://clinicaltrials.gov/study/NCT00267865","created_at":"2021-01-18T00:54:41.110Z","updated_at":"2024-07-02T16:36:44.616Z","phase":"Phase 2","brief_title":"Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma","source_id_and_acronym":"NCT00267865","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • methotrexate • leucovorin calcium • Xatmep (methotrexate oral solution) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/14/2006","start_date":" 09/14/2006","primary_txt":" Primary completion: 09/18/2019","primary_completion_date":" 09/18/2019","study_txt":" Completion: 09/19/2019","study_completion_date":" 09/19/2019","last_update_posted":"2020-06-01"},{"id":"407ac7e6-0c0a-45e1-bb71-0bd4c56bdc2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01848457","created_at":"2021-01-18T08:14:55.358Z","updated_at":"2024-07-02T16:36:48.338Z","phase":"Phase 2","brief_title":"Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy","source_id_and_acronym":"NCT01848457","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" KIM1","pipe":"","alterations":" ","tags":["KIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xatmep (methotrexate oral solution) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 01/04/2016","primary_completion_date":" 01/04/2016","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2020-03-16"},{"id":"8bd18935-92e1-413b-9e77-12c5e21553f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04283955","created_at":"2021-01-18T20:47:49.261Z","updated_at":"2024-07-02T16:36:49.619Z","phase":"","brief_title":"A Retrospective Cohort Study: The Influence of MTHFR C677T and A1298C on the High-dose Methotrexate-Related Toxicities in Pediatric Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04283955","lead_sponsor":"Sun Yat-sen University","biomarkers":" MTHFR","pipe":" | ","alterations":" MTHFR C677T","tags":["MTHFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTHFR C677T"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-02-25"},{"id":"11bc0ad6-91be-4f21-9370-41705e04ad19","acronym":"","url":"https://clinicaltrials.gov/study/NCT02723578","created_at":"2021-01-18T13:19:32.676Z","updated_at":"2024-07-02T16:36:51.406Z","phase":"Phase 2","brief_title":"Pemetrexed and Erlotinib for Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02723578","lead_sponsor":"Yonsei University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-01-13"},{"id":"621fb80b-96ac-4019-a7af-e5bdf7015741","acronym":"","url":"https://clinicaltrials.gov/study/NCT01118624","created_at":"2021-01-18T04:26:10.126Z","updated_at":"2024-07-02T16:36:51.824Z","phase":"Phase 2","brief_title":"Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer","source_id_and_acronym":"NCT01118624","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Folotyn (pralatrexate)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 07/01/2012","study_completion_date":" 07/01/2012","last_update_posted":"2020-01-07"},{"id":"3d931a31-b046-492c-8fd8-af76f3577629","acronym":"PROPEL","url":"https://clinicaltrials.gov/study/NCT00364923","created_at":"2021-01-18T01:15:54.958Z","updated_at":"2024-07-02T16:36:52.212Z","phase":"Phase 2","brief_title":"Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT00364923 - PROPEL","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" TCL1A","pipe":"","alterations":" ","tags":["TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Folotyn (pralatrexate)"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 01/01/2009","primary_completion_date":" 01/01/2009","study_txt":" Completion: 02/24/2009","study_completion_date":" 02/24/2009","last_update_posted":"2019-12-19"},{"id":"959da17f-f16c-4ad7-a13d-6cf93d57fce2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01469000","created_at":"2021-01-17T17:25:21.150Z","updated_at":"2024-07-02T16:36:55.875Z","phase":"Phase 2","brief_title":"A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT01469000","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 195","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2019-09-10"},{"id":"5c5b12d5-406a-4ca7-97de-ed17104be397","acronym":"","url":"https://clinicaltrials.gov/study/NCT03992885","created_at":"2021-01-18T19:37:48.076Z","updated_at":"2024-07-02T16:36:58.766Z","phase":"Phase 3","brief_title":"Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.","source_id_and_acronym":"NCT03992885","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Conmana (icotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2019-06-20"},{"id":"2c963528-7afd-4228-bbe1-de43b927ac81","acronym":"","url":"https://clinicaltrials.gov/study/NCT00083031","created_at":"2021-01-18T00:14:08.035Z","updated_at":"2024-07-02T16:36:59.407Z","phase":"Phase 2","brief_title":"Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT00083031","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • ER positive + PGR positive • PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cyclophosphamide • methotrexate • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 07/01/2003","start_date":" 07/01/2003","primary_txt":" Primary completion: 08/01/2006","primary_completion_date":" 08/01/2006","study_txt":" Completion: 08/01/2009","study_completion_date":" 08/01/2009","last_update_posted":"2019-05-21"}]